SCHEMBL1007348

SCHEMBL1007348

CN(c1ccc2ccccc2c1)C1CCNCC1

nearest known ligand 0.52

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 20/20 0.52
SLC6A2 P23975 18/20 0.52
SLC6A3 Q01959 11/20 0.52
KCNH2 Q12809 8/20 0.49
HTR3A P46098 2/20 0.44
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HTR7 P34969 1/20 0.43
HTR2B P41595 1/20 0.43
HTR4 Q13639 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3315001 0.81 IKBKB (0.49) SLC6A4SLC6A2SLC6A3KCNH2
Hydrochloric Acid SCHEMBL29862799 0.80 IKBKB (0.48) SLC6A4SLC6A2SLC6A3KCNH2
Hydrochloric Acid SCHEMBL23360688 0.80 DOT1L (0.46) SLC6A4SLC6A2SLC6A3KCNH2
Hydrochloric Acid SCHEMBL23360215 0.80 IKBKB (0.51) SLC6A4SLC6A2SLC6A3KCNH2
Hydrochloric Acid SCHEMBL29862933 0.80 IKBKB (0.51) SLC6A4SLC6A2SLC6A3KCNH2
Hydrochloric Acid SCHEMBL23360072 0.80 IKBKB (0.48) SLC6A4SLC6A2SLC6A3KCNH2
SCHEMBL4010135 0.79 SLC18A3 (0.45) SLC6A4SLC6A2SLC6A3HTR2C
Hydrochloric Acid SCHEMBL23360160 0.79 SLC6A2 (0.43) SLC6A4SLC6A2SLC6A3KCNH2
Hydrochloric Acid SCHEMBL29862709 0.79 SLC6A2 (0.43) SLC6A4SLC6A2SLC6A3KCNH2
Hydrochloric Acid SCHEMBL23360263 0.78 TRPV1 (0.46) SLC6A4SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268631-A1 AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
EP-1078928-B1 Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2004-05-12 EP disclosed
US-6486171-B2 USEFUL IN THE TREATMENT OF SOME CENTRAL NERVOUS SYSTEM DISORDERS INCLUDING AS AN ANTIDEPRESSANT; 4-(1-(2-NAPHTHYL)ETHYL)-4- PIPERIDINYL)THIENO(3,2-C)PYRIDINE, FOR EXAMPLE LES LABORATOIRES SERVIER (FR) 2002-11-26 US disclosed
US-20020161228-A1 Piperidine compounds ADIR ET COMPAGNIE 2002-10-31 US disclosed
US-6399616-B1 4-(4-(2-(5-(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL)ETHYL)-1 -PIPERAZINYL)FURO(3,2-C)PYRIDINE; COMBINED SEROTONIN REUPTAKE INHIBITOR AND PARTIAL AGONIST OF 5-HT RECEPTORS; REDUCED LATENCY; DEPRESSION LES LABORATOIRES SERVIER (FR) 2002-06-04 US disclosed
EP-1078928-A1 Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 2001-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161228-A1 Piperidine compounds OTC, NPPA, AQP4 SLC6A4 1106/4885SLC6A2 1089/4885SLC6A3 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.